Dr Krishnansu Sujata Tewari presents data on a randomised phase III study assessing two different chemotherapy regimens with or without bevacizumab during a press conference at the 2013 ASCO Annual Meeting.

The study found that adding bevacizumab prolongs overall survival by an average of four months compared to chemotherapy alone. The study represents the first time a targeted drug has significantly prolonged overall survival for women with metastatic or relapsed cervical cancer.

Visit ecancerNews to read more